Foreword:  John Mendelsohn, MD, President, The University of Texas M. D. Anderson Cancer Center

Preface:  Gabriel N. Hortobagyi, MD, FACP, University of Texas M. D. Anderson Cancer Center, Houston, TX and Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA

Chapter 1.  Introduction and Background   

Gabriel N. Hortobagyi, MD, FACP, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Chapter 2.  Molecular Diagnostic Techniques in Breast Cancer 

Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA

Chapter 3.  Clinical and Molecular Epidemiology of Breast Cancer 

Abenaa Brewster, MD, MHS, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Melissa Bondy, PhD, both of The University of Texas M. D. Anderson Cancer Center, Houston, TX

Chapter 4.  Predisposition for Breast Cancer

Marion Kiechle, MD, Technical University of Munich, Munich, Germany 
Alfons Meindl, PhD, Technical University of Munich, Munich, Germany

Chapter 5.  Screening and Early Detection, Serum and Nipple Aspirates, Routine and Molecular Methods including Reverse Transcriptase-Polymerase Chain Reaction, and Proteomics 

Douglas P. Malinowski, PhD,  Tripath Oncology, Durhasm, NC

Chapter 6.  Genomic and Molecular Classification of Breast Cancer

Christos Sotiriou, MD, Jules Bordet Institute, Free University of Brussels, Belgium
Christine Desmedt, PhD, Jules Bordet Institute, Free University of Brussels, Belgium
Virginie Durbecq, PhD, Jules Bordet Institute, Free University of Brussels, Belgium
Lissandra Dal Lago, MD, Jules Bordet Institute, Free University of Brussels, Belgium
Marc Lacroix, PhD, Jules Bordet Institute, Free University of Brussels, Belgium
Fatima Cardoso, MD, Jules Bordet Institute, Free University of Brussels, Belgium
Martine Piccart, MD, PhD, Jules Bordet Institute, Free University of Brussels, Belgium

Chapter 7.  Cytology: Clinical Sample Procurement and On-Slide Technologies

W. Fraser Symmans, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Chapter 8.  Histopathology of Breast Cancer: Correlation With Molecular Markers

W. Fraser Symmans, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Chapter 9.  Sentinel Lymph Node Dissection and Micrometastasis Detection in Bone Marrow and Lymph Nodes 

Volkmar Müller, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany 
Sabine Kasimir-Bauer, Universitätsklinikum Essen, Essen, Germany
Klaus Pantel, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Chapter 10.  Prognostic and Predictive Factors Overview

Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA
Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany

Chapter 11.  Breast Cancer Cytogenetics, Chromosomal Abnormalities, and Comparative Genomic Hybridization

Mark Watson, MSc, University of Hull, East Yorkshire, United Kingdom
Lynn Cawkwell, PhD, University of Hull, East Yorkshire, United Kingdom

Chapter 12.  DNA Ploidy and S Phase Analysis in Breast Cancer

Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA
Merrill S. Ross, BS, Albany Medical College, Albany, NY
Shahgul Anwar, MD, Albany Medical College, Albany, NY
Ann Boguniewicz, MD, Albany Medical College, Albany, NY

Chapter 13.  Cell Proliferation Markers and Cell Cycle Regulators in Breast Cancer

Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA
Carlos Cordon-Cardo, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Chapter 14.  Targeted Therapy for Cancer: Integrating Diagnostics and Therapeutics 

Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA

Chapter 15.  Hormone Receptors and Hormonal-based Therapy for Breast Cancer

Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA
Gabriel N. Hortobagyi, MD, FACP, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Chapter 16.  HER-2/neu Gene and Protein in Breast Cancer 

Fatima Cardoso, MD, Jules Bordet Institute, Free University of Brussels, Belgium
Virginie Durbecq, MD, Jules Bordet Institute, Free University of Brussels, Belgium
Christos Sotiriou, MD, Jules Bordet Institute, Free University of Brussels, Belgium
Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA

Chapter 17.  Epidermal Growth Factor Receptor and Other Growth Factors and Receptors

Joan Albanell, MD, ICMHO & IDIBAPS, Hospital Clinic, Barcelona, Spain
Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA

Chapter 18.  Tumor-Associated Proteolytic Factors: Markers For Tumor Invasion And Metastasis

Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany
Viktor Magdolen, PhD, Technical University of Munich, Munich, Germany
Eleftherios Diamandis, MD, PhD, Mount Sinai Hospital, New York, NY, and University of Toronto, Ontario, Canada
Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA
Ronald E. Kates, PhD, Technical University of Munich, Munich, Germany
Manfred Schmitt, PhD, Technical University of Munich, Munich, Germany

Chapter 19.  Breast Cancer and Angiogenesis

Manfred Schmitt, PhD, Technical University of Munich, Munich, Germany 
Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany 
Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA

Chapter 20.  Cell Adhesion Markers

H. Höfler, MD, Technical University of Munich, Munich, Germany
B. Luber, PhD, Technical University of Munich, Munich, Germany

Chapter 21.  Programmed Cell Death and Breast Cancer

Xiao-Ming Yin, MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA
Gerald P. Linette, MD, PhD, Washington University School of Medicine, St. Louis, MO, and Millennium Pharmaceuticals, Cambridge, MA

Chapter 22.  Oncogenes 

Andre M. Oliveira, PhD, Brigham & Women’s Hospital, Boston, MA
Jonathan A. Fletcher, MD, both of Brigham & Women’s Hospital, Boston, MA

Chapter 23.  p53 and Tumor Suppressor Genes in Breast Cancer 

Andre M. Oliveira, PhD, Brigham & Women’s Hospital, Boston, MA
Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA
Jonathan A. Fletcher, MD, Brigham & Women’s Hospital, Boston, MA

Chapter 24.  The Ubiquitin–Proteasome Pathway and Breast Cancer 

Robert Z. Orlowski, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

Chapter 25.  DNA Repair and the Maintenance of Genomic Stability in Breast Cancer 

Jennifer E. Quinn, PhD, Cancer Research Centre, Queens University Belfast and Belfast City  Hospital, Belfast, Northern Ireland
Richard D. Kennedy, MD, PhD, Cancer Research Centre, Queens University Belfast and Belfast City  Hospital, Belfast, Northern Ireland
D. Paul Harkin, MD, Cancer Research Centre, Queens University Belfast and Belfast City Hospital, Belfast, Northern Ireland

Chapter 26.  Biologic and Clinical Significance of DNA Gene Methylation and Epigenetics Events in Breast Cancer 

Manel Esteller, MD, PhD, Spanish National Cancer Center, Spain 
Esteban Ballestar, MD, Spanish National Cancer Center, Spain

Chapter 27.  DNA Methylation in Breast Cancer as Diagnostic Markers and Targets for Cancer Therapy

Sabine Maier, PhD, Epigenomics AG, Berlin, Germany
Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany
Manfred Schmitt, PhD, Technical University of Munich, Munich, Germany
John A. Foekens, PhD, Erasmus MC, Rotterdam, The Netherlands
John W. M. Martens, PhD, Erasmus MC, Rotterdam, The Netherlands

Chapter 28.  Pharmacogenetics, Pharmacogenomics, and Predicting Response to Therapy

Lajos Pusztai, MD, PhD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
James Stec, BS, Millennium Pharmaceuticals Inc., Cambridge, MA
Mark Ayers, BS, Bristol Myers Squibb Corp., Princeton, NJ
Jeffrey S. Ross, MD, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Inc., Cambridge, MA
Peter Wagner, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Roman Rouzier, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX 
Fraser Symmans, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Gabriel N. Hortobagyi, MD, FACP, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Chapter 29.  Mammography and Molecular Imaging 

Hernan I. Vargas, MD, Harbor UCLA Medical Center, Torrance, CA
M. Perla Vargas, MD, and
Iraj Khalkhali, MD, all of Harbor UCLA Medical Center, Torrance, California

Chapter 30.  Translation of Molecular Markers to Clinical Practice 

Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany
Christoph Thomssen, MD, Universitats-Klinikum Eppendorf, Hamburg, Germany
Ronald E. Kates, PhD, Technical University of Munich, Munich, Germany

Chapter 31.  Regulatory Aspects and Implications of Molecular Testing in the United States 

Robert Pietrusko, PhD, Millennium Pharmaceuticals, Inc., Cambridge, MA